Abstracts tagged "proteomics"

Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 1687 • ACR Convergence 2024
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Ioannis Parodis¹, Dionysis Nikolopoulos², Julius Lindblom³, Denis Lagutkin³, Lorenzo Beretta⁴, Maria Orietta Borghi⁵, Janique Peyper⁶, Guillermo Barturen⁷, Per-Johan Jakobsson³, Marta Alarcon-Riquelme⁸, Natalia Sherina³ and Helena Idborg⁹, and PRECISESADS Clinical Consortium, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁵Università degli Studi di Milano Statale, Milano, Italy, ⁶Sengenics Corporation Pte Ltd, Singapore, Singapore, ⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁸Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁹Karolinska Institutet, Solna, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Stephen Pennington¹, Ruoyi Zhou², Jonathan Brady², Bruna Wundervald², Andrew Parnell³, Ciarán Duffy², Robert Perryman², James Waddington⁴, Neil McHugh⁵, Deepak Jadon⁶, David Simon⁷, Filippo Fagni⁸, Georg Schett⁹, Fraser Morton¹⁰, Aurelie Najm¹⁰, Stefan Siebert¹¹, Laura Coates¹² and Oliver FitzGerald¹³, ¹UCD, Dublin, Dublin, Ireland, ²Atturos, DUBLIN, Dublin, Ireland, ³NUIM, Maynooth, Ireland, ⁴Agilent, Manchester, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶Cambridge University, Cambridge, United Kingdom, ⁷Charité - Universittsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹³UCD, Dublin 6, Dublin, Ireland
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
Abstract Number: 0778 • ACR Convergence 2024
Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Justin Chou¹, Ricardo Grieshaber-Bouyer², Michelle J Wu³, Christina Bergmann², Jule Taubmann⁴, Fabian Müller⁵, Aline Bozec⁴, Tobias Rothe², Andreas MAckensen⁶, Amber Podoll⁷, Jonathan Gutman⁷, Aiden Haghikia⁸, Dimitrios Mougiakakos⁹, Gary Tong³, Pouya Kheradpour³, Francis Kim¹⁰, Prameela Ramesan¹⁰, Brandon Kwong¹⁰, Kunbin Qu¹⁰, Bishwa Ganguly¹⁰, Dominic Borie¹⁰, James Chung¹⁰ and Georg Schett¹¹, ¹Kyverna Therapeutics, Emeryville, CA, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Verily Life Sciences, South San Francisco, CA, ⁴Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO, ⁸Otto-von-Guericke University, Magdeburg, Germany, ⁹Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, ¹⁰Kyverna Therapeutics, Inc., Emeryville, CA, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a promising advancement in the treatment of autoimmune diseases, including systemic sclerosis (SSc), idiopathic inflammatory myopathy…
Abstract Number: 1709 • ACR Convergence 2024
Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Liqun Diao², Joan Wither³, Igor Jurisica⁴, Vinod Chandran⁵ and Lihi Eder⁶, ¹Women's College Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) affects males and females equally, but differences exist in the clinical presentation and treatment response. The biological mechanisms driving these differences…
Abstract Number: 0816 • ACR Convergence 2024
Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
James Ward¹, Mythri Ambatipudi², Zerai Manna³, Michael Smith⁴, Melissa de los Reyes⁵, Adam Schiffenbauer⁶, Saifur Rahman⁷, Kamelia Zerrouki⁵, Fredrick Miller¹, Mariana Kaplan⁸, Jian-Liang Li¹, Kerry Casey⁹, Lisa Rider¹⁰ and Sarfaraz Hasni⁶, ¹National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Harvard Medical School, Boston, MA, ³NIH, Bethesda, MD, ⁴Horizon Therapeutics, Alexandria, VA, ⁵AstraZeneca, Gaithersburg, MD, ⁶NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁷AstraZeneca, Gaithersburg, ⁸NIAMS/NIH, Bethesda, MD, ⁹Regeneron Pharmaceuticals, Terrytown, NY, ¹⁰NIEHS, NIH, Garrett Park, MD
Background/Purpose: Systemic lupus erythematosus (SLE) and dermatomyositis (DM) are hypothesized to be triggered by shared genetic and environmental factors leading to aberrant activation of innate…
Abstract Number: 1711 • ACR Convergence 2024
Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
Sreemoyee Ghosh¹, Chiara Pastrello², Omar F. Cruz-Correa³, Darshini Ganatra⁴, Katerina Oikonomopoulou³, Melanie Anderson⁵, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Institute of Medical Science, University of Toronto and Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis (Pso) is a chronic immune mediated inflammatory skin disease. Up to 24% of Pso patients develop psoriatic arthritis (PsA). Pathophysiology of PsA is…
Abstract Number: 0831 • ACR Convergence 2024
JDM Proteomic Signature at Disease Onset and Progression Highlights Persistent Dysregulation of Cell Death, Redox and Innate Immune Signaling
Jessica Neely¹, Jeff Dvergsten², Zilan Zheng¹, Chioma Madubata³, Hanna Kim⁴, Sara Sabbagh⁵, Sophia Matossian⁶, Christine Goudsmit⁶, Celine Berthier⁶ and Jessica Turnier⁷, and for the CARRA Registry Investigators and Translational Medicine for Juvenile Myositis Working Group, ¹UCSF, San Francisco, CA, ²Duke University Hospital, Hillsborough, NC, ³University of California, San Francisco, San Francisco, CA, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) patients frequently have incomplete response to therapy. We utilized exploratory proteomics to advance understanding of dysregulated proteins and biological pathways that…
Abstract Number: 1777 • ACR Convergence 2024
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Amy Kaneshiro¹, Adeline Chin¹, Lisa Rider², Frederick Miller³, Foo Cheung⁴, Megan Darrell¹, Angelique Biancotto⁴, Ujana Zajmi¹ and Hanna Kim⁵, ¹NIH/NIAMS, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³NIH, NIEHS, Chapel Hill, NC, ⁴NIH/NIAID, Bethesda, MD, ⁵National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a heterogenous systemic autoimmune disease with muscle and skin pathology, which can be clinically subgrouped by MSAs (ex: anti-TIF1, anti-MDA5 autoantibodies (Ab)).…
Abstract Number: 0886 • ACR Convergence 2024
A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Chenxi Zhu¹, Siyu He², Yi Liu³, Rui Sun¹ and Yi Zhao⁴, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ²West China Hospital Sichuan University, chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex systemic inflammatory autoimmune disease with a high incidence, primarily affecting the joints. However, it currently lacks definitive biomarkers…
Abstract Number: 1781 • ACR Convergence 2024
Tear Proteomics as a Classifier of Disease Type and Activity Status in Pediatric Uveitis
Melissa Lerman¹, Devlin Eckardt¹, Stefanie Davidson² and Edward Behrens³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania/CHOP, Philadelphia, PA, ³Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Measurement of proteins from tear fluid represents a non-invasive means to assess the local biology of ocular autoimmune disease such as uveitis. Pediatric uveitis…
Abstract Number: 0939 • ACR Convergence 2023
HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease
David Lauer¹, Luca Romano Kolly¹, Hubert Gabrys², Matthias Brunner¹, Malgorzata Anna Maciukiewicz¹, Thomas Frauenfelder³, Stephanie Tanadini-Lang², Anne-Christine Uldry⁴, Manfred Heller⁴, Kerstin Klein⁵, Oliver Distler⁶, Janine Gote-Schniering¹ and Britta Maurer⁷, ¹University Hospital Bern, Bern, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Bern, Bern, Switzerland, ⁵Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
Abstract Number: 2495 • ACR Convergence 2023
Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Natalie Atallah¹, Vahe Panossian², Xiaoqing Fu¹, Claire Cook¹ and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²American University of Beirut, Beirut, Lebanon, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Samir Rachid Zaim¹, Adam Savage¹, Mark Gillespie¹, Christy Bennett¹, lynne Becker¹, LauraKay Moss², Marie Feser², Jess Edison³, Ted R Mikuls⁴, Michael Holer², kevin Deane² and Xiao-Jun Li¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³Walter Reed Military Medical Center, Bethesda, MD, ⁴Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].